The french neonatal screening of cystic fibrosis;Mucoviscidose: Un dépistage pour toute la France

Annales de Biologie Clinique

Volumn 60, Issue 6, 2002, Pages 693-695

  Feldmann, D ^a  

^a ARMAND TROUSSEAU HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CFTR PROTEIN, HUMAN; TRANSMEMBRANE CONDUCTANCE REGULATOR;

AMINO ACID SUBSTITUTION; ARTICLE; CYSTIC FIBROSIS; FRANCE; GENETICS; HUMAN; METHODOLOGY; NEWBORN; NEWBORN SCREENING;

AMINO ACID SUBSTITUTION; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FRANCE; HUMANS; INFANT, NEWBORN; NEONATAL SCREENING;

EID: 17744417972     PISSN: 00033898     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Farrell PM, Kosorok MR, Rock MJ, et al. Early diagnosis of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth. Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 2001; 107: 1-13.
2. Siret D, Branger B, Storni V, et al. Does neonatal screening of cystic fibrosis affect outcome? Comparative study of two cohorts in Britanny and Loire-Atlantique with follow-up after ten years Arch Pediatr 2000; 7: 1154-62.
3. Scotet V, de Braekeleer M, Roussey M, et al. Neonatal screening for cystic fibrosis in Brittany, France: Assessment of 10 years' experience and impact on prenatal diagnosis. Lancet 2000; 356: 789-94.
4. Massie RJ, Olsen M, Glazner J, Robertson CF, Francis I. Newborn screening for cystic fibrosis in Victoria: 10 Years' experience (1989-1998). Med J Aust 2000; 172: 584-7.
5. Castellani C, Bonizzato A, Cabrini G, Mastella G. Newborn screening strategy for cystic fibrosis: A field study in an area with high allelic heterogeneity. Acta Paediatr 1997; 86: 497-502.
6. Claustres M, Guittard C, Bozon D, et al. Spectrum of CFTR mutations in cystic fibrosis and in congenital absence of the vas deferens in France. Hum Mutat 2000; 16: 143-56.
7. Guillot M, Travert G, Roussey M, Figarella C, Vidailhet M. Systematic neonatal screening. Arch Pediatr 2001; 8 (Suppl. 5 ): 833s-7s.
8. Feldmann D, Guittard C, Georges MD, et al. Genetic testing for cystic fibrosis: Evaluation of the Elucigene CF20 kit in blood and buccal cells. Ann Biol Clin 2001; 59: 277-83.
9. Padoan R, Bassotti A, Seia M, Corbetta C. Negative sweat test in hypertrypsinaemic infants with cystic fibrosis carrying rare CFTR mutations. Eur J Pediatr 2002; 161: 212-5.
10. Wilcken B, Wiley V, Sherry G, Bayliss U. Neonatal screening for cystic fibrosis: A comparison of two strategies for case detection in 1.2 million babies. J Pediatr 1995; 127: 965-70.
11. Desmarquest P, Feldmann D, Tamalat A, et al. Genotype analysis and phenotypic manifestations of children with intermediate sweat chloride test results. Chest 2000; 118: 1591-7.
12. Rosenstein BJ, Cutting GR. The diagnosis of cystic fibrosis: A consensus statement. Cystic Fibrosis Foundation Consensus Panel. J Pediatr 1998; 132: 589-95.